ATE381930T1 - Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor - Google Patents

Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor

Info

Publication number
ATE381930T1
ATE381930T1 AT02787507T AT02787507T ATE381930T1 AT E381930 T1 ATE381930 T1 AT E381930T1 AT 02787507 T AT02787507 T AT 02787507T AT 02787507 T AT02787507 T AT 02787507T AT E381930 T1 ATE381930 T1 AT E381930T1
Authority
AT
Austria
Prior art keywords
inhibitor
growth factor
selective cyclooxygenase
factor receptor
receptor tyrosine
Prior art date
Application number
AT02787507T
Other languages
English (en)
Inventor
Ying-Nan Chen
Peter Lassota
Alexander Wood
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE381930T1 publication Critical patent/ATE381930T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT02787507T 2001-10-25 2002-10-24 Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor ATE381930T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34473501P 2001-10-25 2001-10-25
US34473401P 2001-10-25 2001-10-25
US33603301P 2001-11-15 2001-11-15

Publications (1)

Publication Number Publication Date
ATE381930T1 true ATE381930T1 (de) 2008-01-15

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787507T ATE381930T1 (de) 2001-10-25 2002-10-24 Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor

Country Status (23)

Country Link
US (2) US20050043409A1 (de)
EP (1) EP1441714B1 (de)
JP (1) JP2005506366A (de)
KR (1) KR100954625B1 (de)
CN (1) CN100506224C (de)
AT (1) ATE381930T1 (de)
AU (2) AU2006252156A1 (de)
BR (1) BR0213486A (de)
CA (1) CA2464309C (de)
CY (1) CY1108045T1 (de)
DE (1) DE60224299T2 (de)
DK (1) DK1441714T3 (de)
ES (1) ES2295428T3 (de)
HK (1) HK1068261A1 (de)
HU (1) HUP0600235A3 (de)
IL (1) IL161462A0 (de)
MX (1) MXPA04003878A (de)
NZ (2) NZ532418A (de)
PL (1) PL369305A1 (de)
PT (1) PT1441714E (de)
RU (1) RU2333754C2 (de)
SI (1) SI1441714T1 (de)
WO (1) WO2003035047A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
BRPI0413876A (pt) 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
WO2005027972A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
JP2007505939A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と他の治療剤の組み合わせ
BRPI0418102A (pt) 2003-12-23 2007-04-27 Pfizer derivados de quinolina
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
EP2065054A1 (de) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Kombinationen mit einem Prostaglandin und Verwendungen davon
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1479385E (pt) * 1996-10-15 2008-09-02 Searle Llc Utilização de inibidores de ciclo-oxigenase 2 no tratamento e na prevenção de neoplasias
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
IL143901A0 (en) * 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
KR20020018201A (ko) * 1999-08-12 2002-03-07 윌리암 에이취 캘넌, 에곤 이 버그 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물
JP2003517475A (ja) * 1999-12-03 2003-05-27 ファイザー・プロダクツ・インク 抗炎症／鎮痛薬としてのヘテロシクロ−アルキルスルホニルピラゾール誘導体
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
EP1259237A4 (de) * 2000-02-17 2004-07-28 Merck & Co Inc Behandlung und prophylaxe des prostatakrebs mit cox-2 selektiven inhibitoren
WO2001062252A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001232175B2 (en) * 2000-03-03 2005-07-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
NZ532418A (en) 2007-02-23
PT1441714E (pt) 2008-03-10
KR20040048992A (ko) 2004-06-10
DK1441714T3 (da) 2008-03-31
HUP0600235A2 (en) 2007-02-28
SI1441714T1 (sl) 2008-06-30
HUP0600235A3 (en) 2008-04-28
AU2010200433A1 (en) 2010-02-25
DE60224299D1 (de) 2008-02-07
RU2333754C2 (ru) 2008-09-20
EP1441714B1 (de) 2007-12-26
PL369305A1 (en) 2005-04-18
EP1441714A2 (de) 2004-08-04
ES2295428T3 (es) 2008-04-16
NZ552335A (en) 2008-11-28
JP2005506366A (ja) 2005-03-03
DE60224299T2 (de) 2008-12-11
AU2006252156A1 (en) 2007-01-18
BR0213486A (pt) 2005-05-10
CN100506224C (zh) 2009-07-01
WO2003035047A3 (en) 2003-10-23
KR100954625B1 (ko) 2010-04-27
MXPA04003878A (es) 2004-07-08
CN1575168A (zh) 2005-02-02
RU2004116069A (ru) 2005-06-10
US20050043409A1 (en) 2005-02-24
WO2003035047A2 (en) 2003-05-01
CA2464309C (en) 2012-01-03
HK1068261A1 (en) 2005-04-29
US20110046190A1 (en) 2011-02-24
CA2464309A1 (en) 2003-05-01
CY1108045T1 (el) 2013-09-04
IL161462A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
MY151032A (en) Treatment of tnf? related disorders
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
DE60233261D1 (de) Inhibitoren von humanem adam-10
GB0121494D0 (en) Compounds
DE60228616D1 (de) Verwendung von anastrozol zur behandlung von postmenopausalen frauen mit frühzeitigem brustkrebs
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
NO20040973L (no) Anvendelse av 4-pyridylmetylftalaziner for kreftbehandling
ATE400268T1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE373661T1 (de) 1.3.4-triaza-phenalen- und 1,3,4,6- tetraazaphenalen-derivative
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
UA41034A (uk) Спосіб лікування хворих із злоякісними пухлинами сечового міхура
WO2004044226A3 (en) Induction of cellular senescence by cdk4 disruption for tumor supression and regression
UA40408A (uk) Спосіб комбінованого лікування раку щитовидної залози
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
UY27768A1 (es) 2-(2,6- diclorofenil)-diarilimidazoles
UA67528A (en) Method for surgical treatment of thyroid cancer
AU2013204153A1 (en) Treatment of TNFalpha related disorders
ATE297745T1 (de) Chemische modifizierung von harn von säugern
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1441714

Country of ref document: EP